News

In this multicenter, randomized, double-blind phase III QUARTZ study (ClinicalTrials.gov Identifier: NCT02892344), once-daily, low dose IND/MF (QMF149) 150/80 Mu g met the primary and key secondary endpoints (trough

Xeomin is claimed to be the first and only neurotoxin with this approved indication in the EU. It secured approval from the US Food and Drug Administration (FDA)

Souvien is founded on the pioneering research of Professor Li-Huei Tsai, the director of The Picower Institute for Learning and Memory at MIT, and Associate Professor Stephen Haggarty,

The Swiss pharma company is looking for a conditional marketing authorization (CMA) for idebenone for DMD patients who are not using glucocorticoids for the treatment of their respiratory

Revlimid plus rituximab is claimed to be the FDA-approved combination treatment regimen for patients with these indolent forms of non-Hodgkin’s lymphoma (NHL), which does not include chemotherapy. Celgene

“Our collaboration with Hansoh Pharma strengthens our ability to commercialize inebilizumab throughout the world,” commented Bing Yao, Ph.D., Viela’s Executive Chairman and Chief Executive Officer. “Their significant commercial,

CNTX-0290 is a small molecule somatostatin receptor type 4 (SSTR4) agonist, which is being evaluated for the treatment of chronic pain conditions in a phase 1 clinical trial.

Transgene confirms that the study’s primary endpoint (objective response rate – ORR) on a minimum of 35 evaluable patients will be reported in Q4 2019. The Phase 2

The settlement resolves the state’s claims against Teva. The settlement does not establish any wrongdoing on the part of the company; Teva has not contributed to the abuse